Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 1,900 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 1,900 shares of Arcus Biosciences stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $26.00, for a total value of $49,400.00. Following the transaction, the chief accounting officer directly owned 27,363 shares of the company’s stock, valued at $711,438. The trade was a 6.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Alexander Azoy also recently made the following trade(s):

• On Monday, September 29th, Alexander Azoy sold 2,831 shares of Arcus Biosciences stock. The shares were sold at an average price of $13.00, for a total transaction of $36,803.00.
• On Friday, September 5th, Alexander Azoy sold 1,579 shares of Arcus Biosciences stock. The shares were sold at an average price of $11.88, for a total value of $18,758.52.

Arcus Biosciences Price Performance

Shares of RCUS traded down $0.08 during trading hours on Monday, reaching $26.02. 2,620,217 shares of the company’s stock traded hands, compared to its average volume of 1,129,761. Arcus Biosciences, Inc. has a 12 month low of $6.50 and a 12 month high of $26.32. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 0.22. The stock has a market cap of $2.81 billion, a PE ratio of -7.56 and a beta of 0.74. The firm’s 50 day simple moving average is $17.95 and its 200-day simple moving average is $12.60.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. During the same period last year, the firm posted ($1.00) earnings per share. Arcus Biosciences’s quarterly revenue was down 45.8% on a year-over-year basis. Equities analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Hedge Funds Weigh In On Arcus Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank lifted its position in Arcus Biosciences by 3.9% during the 3rd quarter. Amalgamated Bank now owns 19,533 shares of the company’s stock valued at $266,000 after acquiring an additional 736 shares during the period. Creative Planning raised its stake in Arcus Biosciences by 2.7% during the third quarter. Creative Planning now owns 29,629 shares of the company’s stock valued at $403,000 after buying an additional 771 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Arcus Biosciences by 59.1% in the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after acquiring an additional 1,021 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Arcus Biosciences by 8.0% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company’s stock worth $142,000 after purchasing an additional 1,294 shares during the last quarter. Finally, Parallel Advisors LLC increased its stake in Arcus Biosciences by 1.6% during the 2nd quarter. Parallel Advisors LLC now owns 88,007 shares of the company’s stock valued at $716,000 after purchasing an additional 1,422 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on RCUS. Wedbush set a $35.00 price objective on Arcus Biosciences and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Wells Fargo & Company boosted their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Monday, October 20th. The Goldman Sachs Group increased their target price on Arcus Biosciences from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Finally, HC Wainwright increased their price target on shares of Arcus Biosciences from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.44.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.